Cystatin SN (CST1) Is a Poor Independent Prognostic Biomarker for Gastrointestinal Diffuse Large B-cell Lymphoma
Medical Science Monitor · 2024
DOI: 10.12659/msm.943551 ↗Kurz gefasst
Fachartikel in der Zeitschrift Medical Science Monitor, 2024. Verfasst von Jie Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The Second Affiliated Hospital of Shandong First Medical University, Taian, Shandong, China (mainland). Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Biomarkers, Tumor, Gastrointestinal Neoplasms. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Hematology, The Second Affiliated Hospital of Shandong First Medical University, Taian, Shandong, China (mainland).
- Tai'an Disabled Soldiers' Hospital of Shandong Province, Taian, Shandong, China (mainland).
Zitieren
APA
Wang, J., Yang, M., Chen, S., Zhu, H., & Zhang, Z. (2024). Cystatin SN (CST1) Is a Poor Independent Prognostic Biomarker for Gastrointestinal Diffuse Large B-cell Lymphoma. Medical Science Monitor. https://doi.org/10.12659/msm.943551
Vancouver
Wang J, Yang M, Chen S, Zhu H, Zhang Z. Cystatin SN (CST1) Is a Poor Independent Prognostic Biomarker for Gastrointestinal Diffuse Large B-cell Lymphoma. Medical Science Monitor. 2024. doi:10.12659/msm.943551
BibTeX
@article{Wang2024,
author = {Wang, Jie and Yang, Ming and Chen, Sheng and Zhu, Hongbo and Zhang, Zhirong},
title = {Cystatin SN (CST1) Is a Poor Independent Prognostic Biomarker for Gastrointestinal Diffuse Large B-cell Lymphoma},
journal = {Medical Science Monitor},
year = {2024},
doi = {10.12659/msm.943551}
}
EUVIMED